1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Gene Therapy’s Bittersweet Approvals

Two FDA Approvals Could Herald Two Different Financial Outcomes

 
• By Andy Smith

There are instances where the FDA approval of an unpartnered drug is the worst outcome for a biotech company. We may have just seen the first such gene therapy example.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

When the FDA approved two gene therapies for sickle cell disease on the same day, adjectives like “momentous” were wheeled out. While the approvals were certainly landmarks, the commercialization that follows may disappoint.

Two weeks before the Christmas holidays, the FDA approved two gene therapies for sickle cell disease (SCD) – an inherited...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.